LFST: Revenue grew 25%, while FY 2026 revenue and EBITDA guidance rose

What happened

LifeStance Health reported that third-quarter revenue grew 25% year over year and Adjusted EBITDA, a measure of operating earnings, rose 70%. It also reported stronger margins and visit growth, and raised its fiscal 2026 revenue, Center Margin, and Adjusted EBITDA guidance.

Confirmed

Global impact / market context

Higher revenue and visits indicate increased business activity, while faster growth in Adjusted EBITDA and stronger margins suggest more operating earnings from that activity. Raising full-year guidance signals management expects stronger results, which could influence investor expectations for future revenue and profitability.

Analyst inference

The supplied information gives growth rates and raised guidance but no absolute revenue, earnings, or forecast figures. Investors therefore cannot assess the business's scale or compare the outlook with prior expectations from this summary alone; those details could affect how meaningful the upgrade is.

Analyst inference

What to watch

1. Check the full third-quarter results for actual revenue, Adjusted EBITDA, and visit figures; the supplied summary provides growth rates but not the underlying amounts. Analyst inference
2. Look for the revised fiscal 2026 revenue, Center Margin, and Adjusted EBITDA guidance figures, which would show the size of the increases. Analyst inference
3. Assess whether visit growth and stronger margins continue, since sustained activity and improved profit per sale could support the raised full-year outlook. Analyst inference

Evidence

• Original source link unavailable